描述
Carbamazepine is a potent CYP3A4 inducer that markedly increases dexamethasone clearance, reducing its plasma concentrations by 50–80% and risking loss of anti-inflammatory and immunosuppressive efficacy.
机制
Carbamazepine upregulates CYP3A4 (the primary enzyme metabolising dexamethasone), accelerating hepatic and intestinal first-pass metabolism of the corticosteroid and reducing bioavailability.
临床意义
Clinically documented in neuro-oncology patients receiving dexamethasone for cerebral edema who are concurrently on carbamazepine for seizures; standard dexamethasone doses may be sub-therapeutic.
处理措施
Double the dexamethasone dose when carbamazepine is used concurrently; monitor clinical efficacy; strongly consider levetiracetam as an alternative non-enzyme-inducing anticonvulsant in this population.